Avid Bio field­ing client in­quiries due to Chi­na bill; Ox­ford Bio wants to dou­ble its rev­enues

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more.

Avid Bioser­vices has de­tect­ed an uptick in client in­ter­est in the wake of the Biose­cure Act and the No­vo-Catal­ent ac­qui­si­tion, CEO Nicholas Green said dur­ing the com­pa­ny’s first-quar­ter earn­ings call Mon­day, ac­cord­ing to an Al­phaSense tran­script. “It’s fair to say that there seems to be some cor­re­la­tion be­tween those events and the num­ber of op­por­tu­ni­ties that we’re see­ing ma­te­ri­al­ize at the ear­ly stage of dis­cus­sions at the be­gin­ning of this year,” Green said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER